Article

One Patient Diagnosed With Primary Refractory Diffuse Large B Cell Lymphoma Successfully Salvaged With BCL2 Inhibitor Followed by anti-CD19 CAR-T Suffered From a Secondary Onset of Severely CRS

2021-02-01

Abstract excerpt

<h4>Background: </h4> Treatment of relapsed/refractory diffuse large B cell lymphoma (DLBCL) eligible for transplantation is limited by the efficacy of salvage therapy. Chimeric antigen receptor modified T cell (CAR-T) therapy has achieved the highest response rate of salvage therapy for relapsed/refractory aggressive B cell lymphoma. Cytokine release syndrome (CRS) and cytopenia are main side effects of CAR-T the...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: b2ba0c2f-130c-5d68-83f1-8e7a58021dce
DOI: 10.21203/rs.3.rs-174269/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

One Patient Diagnosed With Primary Refractory Diffuse Large B Cell Lymphoma Successfully Salvaged With BCL2 Inhibitor Followed by anti-CD19 CAR-T Suffered From a Secondary Onset of Severely CRSDOI 10.21203/rs.3.rs-174269/v1Read

Lenalidomide overcomes the resistance to third-generation CD19-CAR-T cell therapy in preclinical models of diffuse large B-cell lymphomaSemantic proximity Read

Comparative Effectiveness of CAR T-Cell Therapy versus Blinatumomab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A prospective cohort studySemantic proximity Read

Case report: Sandwich therapy of CAR-T combined with ASCT: Sequential CAR-T cell therapy with ASCT after remission with CAR-T therapy caused long-term survival in a patient with relapsed/refractory Burkitt's lymphoma with TP53 mutations.Semantic proximity Read

TP53 mutations and baseline lymphocytes indicate response to glofitamab in relapsed or refractory diffuse large B-cell lymphoma.Semantic proximity Read

Tandem CD19/CD22 CAR-T cells conquer high-risk cytogenetics and acquire complete remission in r/r B-ALL patientsSemantic proximity Read

CD19-directed CAR T-cell therapy in B-cell NHLSemantic proximity Read

CD56-positive diffuse large B-cell lymphoma/leukemia with BCL6/MYC double-hit and multiple gene mutations: an indicator of poor prognosis?Semantic proximity Read

Phase I clinical trial of CD19 CAR-T cells expressing CXCR5 protein for the treatment of relapsed or refractory B-cell lymphomaSemantic proximity Read

[Two cases of EB virus-positive diffuse large B-cell lymphoma with HAVCR2 mutation].Semantic proximity Read

DCZ0014, A Novel Compound in the Therapy of Diffuse Large B-Cell Lymphoma via the B Cell Receptor Signaling PathwaySemantic proximity Read

CD19-directed CAR T-cell therapy for treatment of primary CNS lymphomaSemantic proximity Read

A CAR-T response prediction model for r/r B-NHL patients based on a T-cell subset nomogramSemantic proximity Read